Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1537-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

By  

Psychotherapy and Psychosomatics, Vol. 86, Iss. 5, 2017-09 ,pp. : 260-267

Karger

Access to resources Recommend Favorite

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 6, 2015-06 ,pp. : 1148-1155

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy of a health‐related quality‐of‐life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1091-1094

John Wiley & Sons Inc

Access to resources Recommend Favorite